About Us

Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the prevention and treatment of surgical site infection (SSI). The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for prevention of SSI, including after orthopaedic, cardiac, and colorectal surgery.